AKN-028

DB12746InvestigationalSmall molecule

AKN-028 has been used in trials studying the treatment of Acute Myeloid Leukemia.

Mechanism: Pharmacologically active on Receptor-type tyrosine-protein kinase FLT3
Curator reviewed
Formula / weight: C₁₇H₁₄N₆ · 302.341 g/mol (avg)
Code names: AKN-028

Resolves to

Compound

Structure

InChIKeyJLRIJKVMMZEKDF-UHFFFAOYSA-NSMILESNC1=C(NC2=CC=C3NC=CC3=C2)N=C(C=N1)C1=CC=NC=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with AKN-028, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.